Q1 2025 Divi's Laboratories Ltd Earnings Call Transcript
Key Points
- Divi's Laboratories Ltd (BOM:532488) reported a consolidated revenue of INR2,197 crores for Q1 FY25, marking an 18% year-on-year growth.
- The company achieved a PBT of INR604 crores and a PAT of INR430 crores for the quarter, showing significant improvement from the previous year.
- Divi's Laboratories Ltd (BOM:532488) successfully completed a US FDA inspection at its Unit-II production facility with only one procedural observation.
- The company is experiencing stable demand for its established generics and gaining market share in emerging generic products.
- Divi's Laboratories Ltd (BOM:532488) is advancing its custom synthesis segment with several new projects across all clinical stages, including Phase 2 and Phase 3 molecules.
- The company is facing pricing pressure across its large volume products like Naproxen, Gabapentin, and Dextromethorphan.
- Logistics and supply chain challenges persist, resulting in significant rate hikes and long transit times.
- The nutraceutical business showed no growth in Q1 FY25 compared to the same quarter last year, with revenue remaining flat at INR178 crores.
- Divi's Laboratories Ltd (BOM:532488) has a ForEx loss of INR1 crore for the quarter, compared to a gain of INR3 crores in the corresponding quarter of the previous year.
- The company is cautious about the impact of ongoing geopolitical events and the potential volatility in raw material prices.
Good day and Welcome to the earnings conference call of Divi's Laboratories Limited for Q1 FY25. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. M. Satish Chaudhary. Thank you. over to you sir.
'-&
Okay, good afternoon to all of you. I am M. Satish Chaudhary, Company Secretary and Chief Investor Relations Officer of Divi's Laboratories Limited. I welcome you all to the earnings call of the company for the quarter ended 30 June 2024. From Divi's Lab We have with us today, Dr. Kiran S Divi, Whole-Time Director and CEO, Nilima Prasad Divi, Whole-Time Director, Commercial; Mr. L. Kishore Babu, Chief Financial Officer; and Mr. Venkatesa Perumallu, General Manager, Finance and Accounts.
During the day, our Board has approved the unaudited financial results for the quarter ended June 30, 2024, and we have released the same to the stock exchanges as well as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
